"Latvia Pharmaceuticals & Healthcare Report Q1 2015" Published

Market growth forecasts are strong although the country will continue to present a modest opportunity to larger multinational companies on account of its relatively small market size. Meanwhile, tensions between Ukraine and Russia may provide challenges for local manufacturers that had sought exports to Russia and the Commonwealth of Independent States (CIS) region as a remedy for lacklustre domestic demand in recent years.

Headline Expenditure Projections

* Pharmaceuticals: EUR325mn (USD429mn) in 2013 to EUR340mn (USD456mn) in 2014; +4.7% in local currency terms and +6.3% in US dollar terms.
* Healthcare: EUR0.94bn (USD1.24bn) in 2013 to EUR0.98bn (USD1.31bn) in 2014; +4.2% in local currency terms and +5.8% in US dollar terms.

Full Report Details at
- http://www.fastmr.com/prod/904284_latvia_pharmaceuticals_healthcare_report_q1_2015.aspx?afid=301

Risk/Reward Index: Latvia is ranked 12th out of the 20 countries surveyed in the Central and Eastern Europe (CEE) region in Q115. Its relative position in the rankings remains unchanged from our assessment for the previous quarter. Latvia's overall score also remains unchanged at 50.0 for Q115. Latvia's score remains below the regional average of 51.0, indicating the country's challenging business environment, particularly in terms of potential industry rewards. Consequently, direct multinational operations are limited and domestic companies such as Grindeks have looked abroad for growth opportunities.

Key Trends And Developments

* In June 2014, Grindeks reported that it had made an advance payment of EUR11.67mn as part of a 2012 deal to acquire Slovakia-based company, HBM Pharma, in a deal worth EUR13.1mn. The remaining amount of the payment will be made after the re-registration of shares to Grindeks according to Slovak legislation. Grindeks commented that it anticipates the transaction to be completed in 2014; following completion, HBM Pharma will be included in Grindeks' Group structure.

BMI Economic View: The escalation of a major trade war between Russia and the EU will have ramifications for Latvia's external...

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Slovenia Pharmaceuticals & Healthcare Report Q1 2015
- Thailand Pharmaceuticals & Healthcare Report Q1 2015
- Kenya Pharmaceuticals & Healthcare Report Q1 2015
- Hong Kong Pharmaceuticals & Healthcare Report Q1 2015
- Croatia Pharmaceuticals & Healthcare Report Q1 2015